Philippe Beuzeboc

12.8k total citations · 3 hit papers
243 papers, 7.6k citations indexed

About

Philippe Beuzeboc is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Philippe Beuzeboc has authored 243 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 136 papers in Pulmonary and Respiratory Medicine, 120 papers in Oncology and 63 papers in Surgery. Recurrent topics in Philippe Beuzeboc's work include Prostate Cancer Treatment and Research (89 papers), Cancer Treatment and Pharmacology (44 papers) and Bladder and Urothelial Cancer Treatments (38 papers). Philippe Beuzeboc is often cited by papers focused on Prostate Cancer Treatment and Research (89 papers), Cancer Treatment and Pharmacology (44 papers) and Bladder and Urothelial Cancer Treatments (38 papers). Philippe Beuzeboc collaborates with scholars based in France, United States and United Kingdom. Philippe Beuzeboc's co-authors include P Pouillart, Stéphane Oudard, Thierry Dorval, Bernard Asselain, Suzy Scholl, Karim Fizazi, M Jouve, Jean‐Yves Pierga, T Palangié and J.C. Durand and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Philippe Beuzeboc

228 papers receiving 7.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

2012 420 citations Philippe Beuzeboc et al. profile →
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

2021 351 citations Scott T. Tagawa, Arjun Vasant Balar et al. Journal of Clinical Oncology profile →
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

2015 315 citations Gwénaëlle Gravis, M. Soulié et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Philippe Beuzeboc	3.9k	3.2k	2.4k	1.6k	1.4k	243	7.6k
Pierre Kerbrat	4.6k 1.2×	2.1k 0.7×	1.9k 0.8×	2.4k 1.5×	647 0.5×	189	8.3k
Alan Horwich	2.6k 0.7×	5.6k 1.7×	1.5k 0.6×	2.4k 1.5×	1.5k 1.1×	140	10.4k
Ugo De Giorgi	3.8k 1.0×	4.7k 1.4×	2.4k 1.0×	2.1k 1.3×	1.1k 0.8×	489	9.0k
Arnoud J. Templeton	5.6k 1.4×	2.6k 0.8×	1.9k 0.8×	1.5k 0.9×	593 0.4×	152	8.6k
Mikhail Lichinitser	7.8k 2.0×	3.8k 1.2×	2.0k 0.9×	1.3k 0.8×	1.3k 0.9×	62	9.9k
Irene Floriani	3.3k 0.9×	2.3k 0.7×	874 0.4×	1.8k 1.1×	1.1k 0.8×	159	8.3k
Ashley E. Winkler	3.9k 1.0×	2.5k 0.8×	848 0.4×	1.4k 0.9×	751 0.5×	12	7.3k
Janine Mansi	3.5k 0.9×	2.3k 0.7×	1.2k 0.5×	998 0.6×	798 0.6×	123	6.5k
Jürgen Dunst	1.8k 0.4×	3.0k 0.9×	1.6k 0.7×	2.4k 1.5×	877 0.6×	234	6.9k
Catherine Van Poznak	5.2k 1.3×	1.7k 0.5×	1.6k 0.7×	764 0.5×	1.1k 0.8×	150	7.3k

Countries citing papers authored by Philippe Beuzeboc

Since Specialization

Citations

This map shows the geographic impact of Philippe Beuzeboc's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Beuzeboc with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Beuzeboc more than expected).

Fields of papers citing papers by Philippe Beuzeboc

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Beuzeboc. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Beuzeboc. The network helps show where Philippe Beuzeboc may publish in the future.

Co-authorship network of co-authors of Philippe Beuzeboc

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Beuzeboc. A scholar is included among the top collaborators of Philippe Beuzeboc based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Beuzeboc. Philippe Beuzeboc is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Radulescu, C., et al.. (2025). Comparison of PERCIST5, imPERCIST5, and PERCIMT Criteria for Early Assessment of Pembrolizumab Response with FDG-PET/CT in Metastatic Bladder Cancer Patients. Pharmaceuticals. 18(5). 701–701.

Galsky, Matt D., Guru Sonpavde, Thomas Powles, et al.. (2024). Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.. Journal of Clinical Oncology. 42(16_suppl). 4509–4509. 11 indexed citations

Loriot, Yohann, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.. (2024). A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer. Future Oncology. 20(23). 1621–1631. 1 indexed citations

Chamorey, Emmanuel, Jean-Marc Ferrero, Hakim Mahammedi, et al.. (2024). Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences. 25(11). 6058–6058.

Heijden, Michiel S. van der, Guru Sonpavde, Thomas Powles, et al.. (2023). LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial. Annals of Oncology. 34. S1341–S1341. 9 indexed citations

Stoeklé, Henri‐Corto, et al.. (2023). Vaccination against HPV: Easier said than done?. Human Vaccines & Immunotherapeutics. 19(3). 2266935–2266935.

Ferrero, Jean-Marc, Hakim Mahammedi, Gwénaëlle Gravis, et al.. (2023). Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer. Pharmaceutics. 15(2). 651–651. 3 indexed citations

Stoeklé, Henri‐Corto, et al.. (2022). Bio‐ethical issues in oncology during the first wave of the COVID‐19 epidemic: A qualitative study in a French hospital. Journal of Evaluation in Clinical Practice. 29(6). 925–933. 1 indexed citations

Vallée, Alexandre, et al.. (2022). Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study. Current Oncology. 29(2). 945–955. 6 indexed citations

10.

Salleron, Julia, et al.. (2021). The Supportive Care sCore (SCC): trigger alert validation study in solid tumours. BMJ Supportive & Palliative Care. 14(e1). e919–e927. 1 indexed citations

11.

Ratta, Raffaele, Annalisa Guida, Florian Scotté, et al.. (2020). PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review. Prostate Cancer and Prostatic Diseases. 23(4). 549–560. 30 indexed citations

12.

Lamy, Pierre‐Jean, Yves Allory, Anne‐Sophie Gauchez, et al.. (2017). Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review. European Urology Focus. 4(6). 790–803. 59 indexed citations

13.

Deshayes, Emmanuel, M. Roumiguié, Constance Thibault, et al.. (2017). Radium 223 dichloride for prostate cancer treatment. Drug Design Development and Therapy. Volume 11. 2643–2651. 68 indexed citations

14.

Vincent‐Salomon, Anne, et al.. (2007). [Reflexion on innovation diffusion factors: the case of Herceptin].. PubMed. 94(3). 297–306. 1 indexed citations

15.

Soulié, M., Philippe Beuzeboc, Pierre Richaud, et al.. (2006). Bulletin de synthèse de veille 2005 Recommandations pour la pratique clinique Prise en charge thérapeutique du cancer de la prostate non métastatique. Bulletin du Cancer. 93(10). 1007–1015.

16.

Pinieux, Gonzague de, et al.. (2004). Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c- erb b-2) status in urothelial carcinoma. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 444(5). 415–419. 24 indexed citations

17.

Vincent‐Salomon, Anne, et al.. (2003). [Targeting epidermal growth factor receptor in cancer of the breast].. PubMed. 90 Spec No. S257–62. 4 indexed citations

18.

Chauveinc, L., et al.. (2002). Concomitant pelvic irradiation and chemotherapy in locally advanced cervical carcinoma. A retrospective study of 92 patients treated at the Curie Institute. Cancer/Radiothérapie. 201–208. 2 indexed citations

19.

Sastre‐Garau, Xavier, Michel Jouve, Bernard Asselain, et al.. (1996). Infiltrating lobular carcinoma of the breast: Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer. 77(1). 113–120. 327 indexed citations

20.

Beuzeboc, Philippe, et al.. (1989). [Hypocalcemic hypomagnesemic coma after carboplatin].. PubMed. 18(27). 1343–4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact